American Trust bought a new stake in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the 1st quarter, Holdings Channel.com reports. The firm bought 580 shares of the company’s stock, valued at approximately $234,000.
Several other institutional investors have also recently bought and sold shares of MEDP. Rise Advisors LLC bought a new stake in shares of Medpace during the 1st quarter worth approximately $27,000. Mather Group LLC. bought a new stake in shares of Medpace during the 1st quarter worth approximately $28,000. Fidelis Capital Partners LLC bought a new stake in shares of Medpace during the 1st quarter worth approximately $31,000. Arcadia Investment Management Corp MI raised its stake in shares of Medpace by 40.3% during the 1st quarter. Arcadia Investment Management Corp MI now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 29 shares in the last quarter. Finally, J.Safra Asset Management Corp raised its stake in shares of Medpace by 87.0% during the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after purchasing an additional 47 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.
Medpace Price Performance
NASDAQ MEDP traded down $8.16 on Friday, reaching $377.00. The stock had a trading volume of 322,082 shares, compared to its average volume of 337,243. The firm has a fifty day moving average of $403.18 and a two-hundred day moving average of $386.08. Medpace Holdings, Inc. has a 1-year low of $227.21 and a 1-year high of $459.77. The company has a market cap of $11.69 billion, a P/E ratio of 38.43, a price-to-earnings-growth ratio of 2.00 and a beta of 1.36.
Insider Transactions at Medpace
In other news, Director Ashley M. Keating 1,300 shares of Medpace stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available through this link. In other news, Director Ashley M. Keating 1,300 shares of Medpace stock in a transaction on Tuesday, July 30th. The was disclosed in a legal filing with the SEC, which is available through this link. Also, CEO August J. Troendle sold 3,987 shares of the stock in a transaction on Friday, May 24th. The stock was sold at an average price of $395.22, for a total value of $1,575,742.14. Following the sale, the chief executive officer now directly owns 660,351 shares in the company, valued at $260,983,922.22. The disclosure for this sale can be found here. In the last three months, insiders have sold 14,519 shares of company stock valued at $5,765,631. 20.30% of the stock is owned by corporate insiders.
Analysts Set New Price Targets
A number of equities research analysts have recently issued reports on the company. Truist Financial assumed coverage on Medpace in a research note on Thursday. They set a “hold” rating and a $415.00 price objective on the stock. Jefferies Financial Group upgraded Medpace from a “hold” rating to a “buy” rating and upped their price objective for the stock from $340.00 to $450.00 in a research note on Tuesday, April 23rd. StockNews.com upgraded Medpace from a “hold” rating to a “buy” rating in a research note on Thursday. Mizuho started coverage on Medpace in a report on Tuesday, May 28th. They set a “buy” rating and a $435.00 target price on the stock. Finally, Robert W. Baird decreased their target price on Medpace from $469.00 to $430.00 and set an “outperform” rating on the stock in a report on Wednesday, July 24th. Two analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $423.00.
Get Our Latest Report on Medpace
Medpace Company Profile
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Further Reading
- Five stocks we like better than Medpace
- Stock Dividend Cuts Happen Are You Ready?
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- How to Calculate Return on Investment (ROI)
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.